Serum tartrate-resistant acid phosphatase 5b is a specific and sensitive marker of bone resorption.
Serum tartrate-resistant acid phosphatase 5b is a specific and sensitive marker of bone resorption.
复制标题
DOI：
10.1093/clinchem/47.3.597
复制
发表时间：
2001-03
影响因子：
9.3
通讯作者：
J. Halleen;S. Alatalo;A. Janckila;H. Woitge;Markus J. Seibel;H. Väänänen
中科院分区：
文献类型：
--
作者：
J. Halleen;S. Alatalo;A. Janckila;H. Woitge;Markus J. Seibel;H. Väänänen
骨吸收破骨细胞和活化的巨噬细胞表达大量 5 型抗酒石酸酸性磷酸酶 (TRACP；EC 3.1.3.2) (1)。破骨细胞将 TRACP 分泌到循环中，血清 TRACP 被认为是骨吸收的潜在有用标志物。一些技术问题阻碍了血清 TRACP 作为骨吸收特异性标志物的使用。由于存在源自血小板和红细胞的干扰酸性磷酸酶，早期的酶测定缺乏特异性 (2)(3)。血清 TRACP 可以通过使用氟化物 (4) 或通过使用 TRACP 特异性抗体进行免疫测定 (5)(6)(7)(8)(9) 来测定。然而，血清中有两种形式的TRACP，即TRACP 5a和TRACP 5b。其中，TRACP 5b 源自破骨细胞，而 TRACP 5a 源自其他尚未确定的来源 (10)(11)(12)。最近开发了两种针对血清 TRACP 5b 的诊断测定法：一种基于使用特异性抑制剂的动力学测定法 (13)，以及一种基于高度表征的特异性单克隆抗体的免疫测定法 (12)。 TRACP 5b 特异性免疫测定已被证明是监测抗骨吸收治疗的有用方法 (12)。我们现在通过研究血清 TRACP 5b 在各种骨疾病和非骨骼疾病中的临床特异性和临床敏感性，进一步表征了免疫测定法。在书面知情同意后，我们从 303 人那里获取了血清样本。在采样时，没有受试者正在接受抗骨质疏松治疗。健康绝经前女性、健康绝经后女性和无骨转移证据的乳腺癌（BC）患者（BC−）被纳入对照人群。有骨病的患者...
Bone-resorbing osteoclasts and activated macrophages express high amounts of type 5 tartrate-resistant acid phosphatase (TRACP; EC 3.1.3.2) (1). Osteoclasts secrete TRACP into the circulation, and serum TRACP has been considered a potentially useful marker of bone resorption. Several technical problems have prevented the use of serum TRACP as a specific marker of bone resorption. Early enzymatic assays lacked specificity because of the presence of interfering acid phosphatases derived from platelets and erythrocytes (2)(3). Serum TRACP can be determined by use of fluoride (4) or by immunoassays with antibodies specific for TRACP (5)(6)(7)(8)(9). However, there are two forms of TRACP in the serum, namely TRACP 5a and TRACP 5b. Of these, TRACP 5b is derived from osteoclasts, whereas TRACP 5a originates from other, as yet unidentified sources (10)(11)(12). Two diagnostic assays have been developed recently for serum TRACP 5b: a kinetic assay based on the use of specific inhibitors (13), and an immunoassay based on a highly characterized specific monoclonal antibody (12). The TRACP 5b-specific immunoassay has been shown to be a useful method for monitoring antiresorptive therapy (12). We have now further characterized the immunoassay by studying the clinical specificity and clinical sensitivity of serum TRACP 5b in various bone diseases and nonskeletal diseases. We obtained serum samples from 303 individuals after written informed consent. At the time of sampling, none of the subjects was receiving antiosteoporotic treatment. Healthy premenopausal women, healthy postmenopausal women, and breast cancer (BC) patients without evidence of bone metastases (BC−) were included as control populations. Patients with bone …